Treatment of drug-induced psychosis in Parkinson's disease with clozapine.
Greene
P
P
Columbia-Presbyterian Medical Center, New York, New York 10032.
Cote
L
L
Fahn
S
S
D000368:Aged; D000978:Antiparkinson Agents / Q000009:adverse effects* / Q000627:therapeutic use; D002230:Carbidopa / Q000009:adverse effects* / Q000627:therapeutic use; D003024:Clozapine / Q000009:adverse effects / Q000627:therapeutic use*; D003704:Dementia / Q000139:chemically induced / Q000188:drug therapy / Q000523:psychology; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004338:Drug Combinations; D005260:Female; D006801:Humans; D007980:Levodopa / Q000009:adverse effects* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009460:Neurologic Examination / Q000187:drug effects; D010300:Parkinson Disease / Q000188:drug therapy* / Q000523:psychology; D011605:Psychoses, Substance-Induced / Q000188:drug therapy* / Q000523:psychology
D000978:Antiparkinson Agents; D004338:Drug Combinations; C009265:carbidopa, levodopa drug combination; D007980:Levodopa; D003024:Clozapine; D002230:Carbidopa